Following the recent move of Graham Kelly from CEO to Executive Chairman, Noxopharm Ltd. announced a series of further planned changes in Board membership for both itself and its subsidiary company, Nyrada Inc. The changes reflect the considerable progress being made in the businesses of both companies, their growing independence from each other, and plans for future listings on security exchanges. Beata Niechoda joined Noxopharm Board. Over the past 6 months, Dr. Niechoda has served as a Special Advisor to the Noxopharm Board, providing the Board with independent advice on the Company's clinical and commercial strategies and objectives. In addition to Board duties, Dr. Niechoda will work closely with the Company's CEO, Dr. Greg van Wyk, and the Company's Global Medical Director, Dr. Gisela Mautner, providing a high-level executive team with broad industry experience driving the Veyonda drug development program and commercial strategy.